Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: L01 - Antineoplastic agentsDrug: L01X - Other antineoplastic agentsDrug: L01XE - Protein kinase inhibitors
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 172
- Registration Number
- NCT03281200
- Locations
- 🇪🇸
Dynamic solutions, Barcelona, Spain
This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT03279978
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: ICS (Inhaled Corticosteroid) (Triple therapy)Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 714
- Registration Number
- NCT03265145
- Locations
- 🇺🇸
Aureus Medical Group, Inc, Rancho Cucamonga, California, United States
🇺🇸HealthCare Partners, Commerce, California, United States
🇺🇸Advanced Research for Health Improvement, LLC, Naples, Florida, United States
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1489
- Registration Number
- NCT03258645
- Locations
- 🇸🇪
SITS International (c/o Karolinska University Hospital), Stockholm, Sweden
This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03259464
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Empagliflozin/linagliptin/metformin HCl
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03259490
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Medical Need of OAC Reversal
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53969
- Registration Number
- NCT03254147
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22490
- Registration Number
- NCT03254134
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 101
- Registration Number
- NCT03242759
- Locations
- 🇨🇳
Chang-Hua Christian Hospital, Changhua, Taiwan
🇨🇳Chang Gung Memorial Hospital(Linkou), Tao-Yuan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT03240575
- Locations
- 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States